Ligand’s Captisol® technology is a patent protected, uniquely modified cyclodextrin, with a chemical structure that was rationally designed to enable the creation of new products by significantly improving solubility, stability, bioavailability and dosing of active pharmaceutical ingredients (APIs).

Captisol Key Advantages

Improved Solubility and Improved Formulations

  • Allows formulation of water-insoluble APIs in all dosage forms, including oral, injectables, ophthalmic, nasal, topical and inhalation products
  • Tastelessness - taste masking in oral, nasal and inhalation preparations
  • Reduction of irritation at site of injection in injectable formula

Improved Bioavailability and Delivery Efficiency

  • Better bioavailability than methods of solubilization using nanoparticles and solvent systems
  • Permits lower dosing of APIs (i.e. potential for dose sparing)

Rapid Onset

  • Potential to enable faster acting versions of many currently approved oral products


  • cGMP manufacturing via a validated process at multi-metric ton commercial scale
  • Well-defined impurity profile and long term stability

Improved Safety, Compatibility and Convenience

  • Excellent safety record and global regulatory validation
  • Broad Drug Master Files in US, Canada and Japan

Learn more at